Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-23
2010-12-21
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07855224
ABSTRACT:
This invention relates to compounds having pharmacological activity, to compositions containing these compounds, and to a method of treatment employing the compounds and compositions. More particularly, this invention concerns certain indole derivatives and their salts and solvates. These compounds have H3histamine receptor antagonist activity. This invention also relates to pharmaceutical compositions containing these compounds and to a method of treating disorders in which histamine H3receptor blockade is beneficial.
REFERENCES:
patent: 3799943 (1974-03-01), Bell et al.
patent: 5399599 (1995-03-01), Guillot
patent: 5631381 (1997-05-01), Huang et al.
patent: 6630496 (2003-10-01), McKew et al.
patent: 2007/0287715 (2007-12-01), Olofsson et al.
patent: WO 93/25524 (1993-12-01), None
patent: WO 99/43672 (1999-09-01), None
patent: WO 2004/099192 (2004-11-01), None
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003 from internet], URL; http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indexhtml>.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 2050-2057.
Arrang et al., “Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor”, Nature vol. 302 28 Apr. 1983, pp. 832-837.
Berge et al., “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences Jan. 1977 vol. 66 No. 1, pp. 1-19.
Carreno et al., “Enantioselective diels-alder cycloadditions with (SS)-2-(p-Tolylsulfinyl)-1,4-naphthoquinone: efficient kinetic resolution of chiral racemic vinylcyclohexenes”, J. Org. Chem. 1998, 63, pp. 8320-8330.
Coward et al., “Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors”, Analytical Biochemistry 270, 1999, pp. 242-248.
Harrington et al., “Creation of genome-wide protein expression libraries using random activation of gene expression”, Nature Publishing Group, May 2001, vol. 19, pp. 440-445.
Inagaki et al., “Organization of histaminergic fibers in the rat brain”, The Journal of Comparative Neurology, 1988 No. 273 pp. 283-300.
Klapars et al., “A general and efficient copper catalyst for the amidation of aryl halides and the N-arylation of nitrogen heterocycles”, J. Am. Chem. Soc. 2001 No. 123, pp. 7727-7729.
Kuyper et al., “High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialky1-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size”, J. Med. Chem. 1996, No. 39, pp. 892-903.
Lin et al., “Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat”, Brain Research, 1990 No. 523, pp. 325-330.
Poste et al., “Lipid vesicles as carriers for introducing biologically active materials into cells”, National Library of Medicine, Dec. 28, 1976, pp. 1-22.
Schwartz, “Minireview histamine as a transmitter in brain”, Life Science vol. 17, pp. 503-518.
Schwartz et al., “Three classes of histamine receptors in brain”, TIPS 1986, pp. 24-28.
Esbenshade et a. “Histamine H3 Receptor Antagonists: Preclinical Promis for Treating Obesity and Cognitive Disorders”, Molecular Interventions, vol. 6, Issue 2, Apr. 2006, Abbott Laboratories, Division of Neuroscience Research, Global Pharmaceutical Research and Development.
Cowart et al., “Medicinal Chemistry and Biological Properties of Non-Imidazole Histamine H3 Antagonists”, Mini-Reviews in Medicinal Chemistry, 2004, 4, 979-992, Bentham Science Publishers Ltd.
Leurs et al., “The histamine H3 Receptor: From Gene Cloning to H3 Receptor Drugs”, Nature Reviews, vol. 4, Feb. 2005, Divisional of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research.
Bennani Youssef L.
Campbell Michael G.
Dastrup David
Porter Huck Emilie
Anderson Rebecca L
Athersys, Inc.
Wood Phillips Katz Clark & Mortimer
Young Shawquia
LandOfFree
Indole derivatives as histamine 3 receptor inhibitors for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole derivatives as histamine 3 receptor inhibitors for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole derivatives as histamine 3 receptor inhibitors for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4150034